Analog Devices (ADI) came out with quarterly earnings of $2.05 per share, beating the Zacks Consensus Estimate of $1.93 per share. This compares to earnings of $1.58 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +6.22%. A quarter ago, it was expected that this semiconductor maker would post earnings of $1.69 per share when it actually produced earnings of $1.85, delivering a surprise of +9.47%.Over the last four quarters, th ...

I have been covering Putnam BDC Income ETF (NYSEARCA: PBDC ) since August, 2024, when I issued my first article suggesting investors, who do not want to dig deep into the BDC space to consider opening aRoberts Berzins has over a decade of experience in the financial management helping top-tier corporates shape their financial strategies and execute large-scale financings. He has also made significant efforts to institutionalize REIT framework in Latvia to boost the liquidity of pan-Baltic capital markets. O ...

Core Viewpoint - Kartoon Studios is launching "Bitcoin Brigade: Adventures in Satoshi City," an innovative animated series that integrates blockchain technology and Bitcoin education into children's entertainment, set to debut in fall 2026 on Kartoon Channel [1][10]. Group 1: Series Overview - "Bitcoin Brigade" invites children into Satoshi City, a digital realm where kids discover a portal connecting their world to a decentralized metropolis, blending action with educational themes [2]. - The series will feature dynamic anime-style visuals and original K-Pop music, aiming to create an immersive experience [2]. - The narrative includes young heroes representing Bitcoin and blockchain concepts, who defend their city from villains threatening the system [6]. Group 2: Business Model and Partnerships - Kartoon Studios is developing a comprehensive Bitcoin-native business platform, including The Satoshi Sparks Rewards System, allowing kids to earn digital currency by engaging with the series [8]. - The company is partnering with Bitkern, a leading Bitcoin mining company, to guide the series and its global launch strategy [2][4]. - A global licensing program will feature toys and apparel embedded with NFC chips to educate children about Bitcoin and blockchain technology [9]. Group 3: Educational Focus - The series aims to teach children about finance, ownership, and innovation through engaging storytelling and interactive challenges [3][8]. - An interactive mobile app will provide secure, kid-friendly Lightning wallets for earning and spending Sparks, with parental controls to promote responsible Bitcoin custodianship [9]. Group 4: Market Positioning - Kartoon Studios positions itself at the forefront of kids' entertainment and blockchain innovation, aiming for a revolutionary impact on entertainment, education, and gaming [1][11]. - The series will be accessible on multiple platforms, including Kartoon Channel and YouTube Kids, ensuring broad engagement [10].

Core Viewpoint - Calidi Biotherapeutics, Inc. has successfully priced a public offering to raise $6 million, indicating strong interest from both existing and new investors despite challenging market conditions [1][2]. Group 1: Offering Details - The offering consists of 1,472,764 common stock units priced at $2.00 each, and 1,528,000 pre-funded warrant units priced at $1.999 each [2]. - Each common stock unit includes one share of common stock and one Series I warrant, while each pre-funded unit includes one pre-funded warrant and one Series I warrant [2]. - The Series I warrants have an exercise price of $2.00 per share and are exercisable upon issuance, expiring five years from issuance [2]. Group 2: Underwriting and Closing - Ladenburg Thalmann & Co. Inc. is the sole book-running manager for the offering, with Laidlaw & Company (U.K.) Ltd. acting as a co-manager [3]. - The underwriters have a 45-day option to purchase an additional 450,000 shares of common stock and/or warrants at the public offering price [3]. - The offering is expected to close on or about August 21, 2025, pending customary closing conditions [3]. Group 3: Company Overview - Calidi Biotherapeutics is a clinical-stage biotechnology company focused on developing targeted therapies for delivering genetic medicines to disease sites [6]. - The company's proprietary Redtail platform utilizes an engineered enveloped oncolytic virus for systemic delivery to metastatic sites, aiming to enhance the effectiveness of virotherapy [6]. - The lead candidate from the Redtail platform is currently in IND-enabling studies, targeting non-small cell lung cancer, ovarian cancer, and other high unmet medical need tumor types [7].

Core Insights - Wrap Technologies, Inc. has launched WrapTactics™, a subscription-based digital learning platform aimed at enhancing officer training and retention of critical skills in policing [1][4][6] - The platform addresses the rapid degradation of police skills due to insufficient training reinforcement, with core defensive tactics deteriorating within two weeks [2][3] - WrapTactics™ is positioned as a growth opportunity for the company, potentially expanding its market into the multi-billion-dollar global training sector [4][6] Product Features - WrapTactics™ offers short-form, high-impact coursework and scenario-based applications to improve skill retention and application under pressure [3][4] - The initial curriculum includes essential skills that could lead to state-certified training content in pre-escalation policing [4] - The platform is available as a standalone product and as part of bundled subscription offerings, enhancing the integration of training and operational support [5] Strategic Positioning - The launch of WrapTactics™ aligns with Wrap's mission to improve public safety outcomes and reduce harm through scalable, technology-enabled training [6] - By leveraging human performance science, Wrap aims to transform modern policing practices and address fundamental training gaps [6] - The company’s BolaWrap 150 solution complements WrapTactics™ by providing a non-lethal option for law enforcement, enhancing officer readiness during critical incidents [7][8]

Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - Coloured Ties Capital Inc. (TSXV: TIE) (OTC Pink: APEOF) (FSE: 97A0) ("CTI" or the "Company") announces it has completed its non-brokered private placement and issued 4,444,444 units of the Company (the "Units") at a price of $0.225 per Unit for gross proceeds of $1,000,000 (the "Offering").Each Unit is comprised of one (1) common share in the capital of the Company (each a "Common Share") and one (1) common share purchase warrant (each a "W ...

Company Overview - Longeveron Inc. is a clinical stage biotechnology company focused on developing regenerative medicines to address unmet medical needs [2] - The company's lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell therapy derived from the bone marrow of young, healthy adult donors [2] - Laromestrocel has multiple potential mechanisms of action, including pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair effects, with applications across various disease areas [2] Pipeline and FDA Designations - Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, Pediatric Dilated Cardiomyopathy (DCM), and Aging-related Frailty [2] - The HLHS program has received three important FDA designations: Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation [2] - The Alzheimer's disease program has received two FDA designations: Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation [2] Upcoming Events - Longeveron will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City [1] - The company's presentation is scheduled for September 8, 2025, from 4:00 to 4:30 p.m. ET, with a webcast available on the company's website [1]

I wrote about The Wendy’s Company (NASDAQ: WEN ) previously with a sell rating, as I did not see hopes for growth to inflect higher given the weak traffic data and poorI am an individual investor that is now fully focus on managing my own capital that I have saved up over the years. My investing background spreads across a wide spectrum as I believe there are merits to each approach, for instance: Fundamental investing [Bottoms-up etc.], Technical investing [historical charts analysis], and to some extend m ...

Target has chosen a veteran company executive to serve as its new CEO.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.Michael Fiddelke, Target’s chief operating officer and former finance chief, will take the chief ...

Core Viewpoint - ROCKWOOL A/S has adjusted its revenue and earnings outlook for the full year 2025 due to a challenging market environment, particularly in North America [2][3]. Group 1: Revenue Outlook - The company expects full-year revenue to be at the same level as last year in local currencies, a change from the previous expectation of low single-digit revenue growth [2][5]. - Revenue for H1 2025 reached 1,947 MEUR, reflecting a one percent increase in both local currencies and reported figures compared to the previous year, with acquisitions in 2024 contributing a two-percentage point positive impact [5]. - Revenue for Q2 2025 was 988 MEUR, showing a two percent decrease in both local currencies and reported figures compared to last year, despite a two-percentage point positive impact from 2024 acquisitions [5]. Group 2: Earnings Outlook - The EBIT margin is now forecasted to be below 16 percent, revised from the previous outlook of around 16 percent [3][5]. - EBIT for H1 2025 decreased by 10 percent to 307 MEUR, with an EBIT margin of 15.8 percent, down 1.9 percentage points compared to H1 2024 [5]. - EBIT for Q2 2025 decreased by 19 percent to 153 MEUR, with an EBIT margin of 15.5 percent, down 3.2 percentage points compared to Q2 2024 [5]. Group 3: Investment Level - The investment level, excluding acquisitions, is maintained at around 450 MEUR [3].